Anzeige
Mehr »
Sonntag, 05.10.2025 - Börsentäglich über 12.000 News
Innocan Pharma: Neues Medikament für den Massenmarkt?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XFUX | ISIN: IL0011313900 | Ticker-Symbol: GPH
Lang & Schwarz
03.10.25 | 07:00
6,500 Euro
-100,00 % -6,500
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GALMED PHARMACEUTICALS LTD Chart 1 Jahr
5-Tage-Chart
GALMED PHARMACEUTICALS LTD 5-Tage-Chart
RealtimeGeldBriefZeit
6,4006,60003.10.

Aktuelle News zur GALMED Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
19.09.Galmed Pharmaceuticals beruft Jährliche Hauptversammlung für den 28. Oktober ein3
19.09.Galmed Pharmaceuticals Ltd. - S-8, Securities to be offered to employees in employee benefit plans2
19.09.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer3
28.08.Galmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update121TEL AVIV, Israel, Aug. 28, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company...
► Artikel lesen
25.08.Galmed to invest up to $10M in digital assets as part of new strategy13
GALMED Aktie jetzt für 0€ handeln
25.08.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer1
18.08.Galmed files to sell 7.5M shares of common stock for holders3
18.08.Galmed Pharmaceuticals Ltd. - F-1, Registration statement for certain foreign private issuers3
15.08.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer1
24.07.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer3
22.05.Galmed GAAP EPS of -$0.62 beats by $0.276
22.05.Galmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update577TEL AVIV, Israel, May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company...
► Artikel lesen
22.05.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer1
13.05.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer1
13.05.Galmed Pharmaceuticals Ltd.: Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models178Aramchol, an SCD1 inhibitor, significantly attenuates and prevents biliary fibrosis in mouse models of primary sclerosing cholangitis (PSC) Aramchol treatment...
► Artikel lesen
06.05.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer6
06.05.Galmed Pharmaceuticals Ltd.: Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models834Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combination significantly reduced hepatic tumor...
► Artikel lesen
02.05.Galmed, Entomus Partner to Introduce Sublingual Semaglutide2
28.04.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer3
17.04.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer2
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1